Neovastat

We recently reported that Neovastat, an antiangiogenic drug that is currently undergoing Phase III clinical trials for the… Expand

Neovastat (AE-941) is an antiangiogenic drug isolated from marine cartilage. It interferes with several steps associated with the… Expand

AE-941 (Neovastat), an antiangiogenic component extracted from cartilage, selectively competes for the binding of vascular… Expand

BACKGROUND renal cell carcinoma (RCC) is a potential target for anti-angiogenic drugs because of its high vascularization… Expand

There is considerable evidence to support an immunopathogenic basis of psoriasis. However, changes such as altered angiogenesis… Expand

Neovastat (AE-941), a naturally occurring multifunctional antiangiogenic agent, has been shown to inhibit key components of the… Expand

A novel naturally occurring antiangiogenic agent isolated from cartilage, referred to as Neovastat (Æ-941), was examined for its… Expand

Bone metastases are generally associated with bone destruction which occurs in response to factors secreted by metastatic cells… Expand

PURPOSE Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, which exerts direct effects on vascular… Expand

Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an… Expand